- Home
- ANGH vs PULM Comparison
ANGH vs PULM Comparison
Compare ANGH & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- PULM
- Stock Information
- Founded
- ANGH 2012
- PULM 2003
- Country
- ANGH United Arab Emirates
- PULM United States
- Employees
- ANGH N/A
- PULM N/A
- Industry
- ANGH Telecommunications Equipment
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- PULM Health Care
- Exchange
- ANGH Nasdaq
- PULM Nasdaq
- Market Cap
- ANGH 32.1M
- PULM 33.2M
- IPO Year
- ANGH N/A
- PULM N/A
- Fundamental
- Price
- ANGH $0.50
- PULM $6.21
- Analyst Decision
- ANGH
- PULM
- Analyst Count
- ANGH 0
- PULM 0
- Target Price
- ANGH N/A
- PULM N/A
- AVG Volume (30 Days)
- ANGH 30.5K
- PULM 58.4K
- Earning Date
- ANGH 07-22-2025
- PULM 08-12-2025
- Dividend Yield
- ANGH N/A
- PULM N/A
- EPS Growth
- ANGH N/A
- PULM N/A
- EPS
- ANGH N/A
- PULM N/A
- Revenue
- ANGH $78,093,405.00
- PULM $1,921,000.00
- Revenue This Year
- ANGH N/A
- PULM N/A
- Revenue Next Year
- ANGH N/A
- PULM $134.88
- P/E Ratio
- ANGH N/A
- PULM N/A
- Revenue Growth
- ANGH 88.72
- PULM N/A
- 52 Week Low
- ANGH $0.42
- PULM $1.78
- 52 Week High
- ANGH $1.08
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- ANGH 48.27
- PULM 41.72
- Support Level
- ANGH $0.47
- PULM $6.28
- Resistance Level
- ANGH $0.65
- PULM $6.83
- Average True Range (ATR)
- ANGH 0.04
- PULM 0.44
- MACD
- ANGH 0.00
- PULM -0.05
- Stochastic Oscillator
- ANGH 16.67
- PULM 13.89
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).